2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-158262
    Bradykinin B1 receptor antagonist 1 578727-81-8
    Bradykinin B1 receptor antagonist 1 (compound 6B) is a potent and cross the blood-brain barrier bradykinin B1 antagonist. Bradykinin B1 receptor antagonist 1 has the potential for the research of pain.
    Bradykinin B1 receptor antagonist 1
  • HY-158334
    NDs-IN-1 3033806-97-9
    (Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases.
    NDs-IN-1
  • HY-158338
    ABHD antagonist 1 3034510-10-3
    ABHD antagonist 1 possesses ABHD6 (α/β-Hydrolase domain containing 6) inhibitory activity, involving the regulation of biochemical pathways involved in ABHD6, thereby affecting cell function and inflammatory response. ABHD antagonist 1 can be used in pain, neuropathic diseases, inflammatory diseases. Autoimmune diseases, metabolic diseases, and cancer research.
    ABHD antagonist 1
  • HY-158339
    ABHD antagonist 2 3034510-43-2
    ABHD antagonist 2 (Compound 9) is an antagonist for alpha/beta-Hydrolase domain containing 6 (ABHD6), with IC50 <0.001 μM. ABHD antagonist 2 exhibits good binding ability with ABHD6, with IC50 of 0.002 μM.
    ABHD antagonist 2
  • HY-158363
    CSF1R-IN-25 2070864-23-0
    CSF1R-IN-25 (compound 36) is an orally effective CSF1R inhibitor. CSF1R-IN-25 can be used to study cancer, inflammation, and neurodegeneration.
    CSF1R-IN-25
  • HY-158365
    LRRK2-IN-14 2942328-06-3
    LRRK2-IN-14 (Compound 8) is an orally active LRRK2 inhibitor. LRRK2-IN-14 has an IC50 of 6.3 nM for LRRK2(G2019S) cell activity.LRRK2-IN-14 has an inhibitory effect on hERG (IC50=22 μM). LRRK2-IN-14 has blood-brain barrier permeability.
    LRRK2-IN-14
  • HY-158376
    mGluR7-IN-1
    mGluR7-IN-1 (compound 2Z) is a mGluR3 inhibitor.
    mGluR7-IN-1
  • HY-158408
    NZ-66 3062992-25-7
    NZ-66 is a UNC-51-like kinase 1 (ULK1) targeting chimera, which is used to achieve proximity-induced and ULK1-dependent degradation of mitochondria. NZ-66 induces mitophagy. NZ-66 is potential for attenuating neurodegenerative disorders.
    NZ-66
  • HY-158410
    PSA-IN-1
    PSA-IN-1 (compound 19) is a puromycin sensitive aminopeptidase (PSA) inhibitor with IC50 at 7 nM. PSA-IN-1 has analgesic activity.
    PSA-IN-1
  • HY-15856A
    Flupentixol 2709-56-0
    Flupentixol is an orally active D1/D2 dopamine receptor antagonist and new PI3K inhibitor (PI3Kα IC50=127 nM). Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research.
    Flupentixol
  • HY-158655
    C17 3'-Sulfo galactosylceramide (d18:1/17:0) 1071654-84-6
    C17 3'-Sulfo galactosylceramide (d18:1/17:0) is a member of the sulfatide class of glycolipids. C17 3'-Sulfo galactosylceramide (d18:1/17:0) can be used for the mass spectrometric quantitative urinary determination in metachromatic leukodystrophies.
    C17 3'-Sulfo galactosylceramide (d18:1/17:0)
  • HY-158693
    WLB-87848 2839205-09-1
    WLB-87848 is a selective, orally active, and blood-brain barrier (BBB) permeable σ1 receptor agonist with the Ki of 9 nM. WLB-87848 rescues recognition memory impairment.
    WLB-87848
  • HY-158695
    Dual AChE-MAO B-IN-4
    Dual AChE-MAO B-IN-4 (compound 7) is a dual AChE/MAO-B inhibitor, with IC50 values ​​of 261 nM and 15 nM, respectively. Dual AChE-MAO B-IN-4 protects against oxidative damage induced by H2O2 and 6-OHDA in SH-SY5Y cells. Dual AChE-MAO B-IN-4 can penetrate the central nervous system in a cell model that mimics the blood-brain barrier. Dual AChE-MAO B-IN-4 can be used in the study of neurological diseases such as Alzheimer's disease (AD).
    Dual AChE-MAO B-IN-4
  • HY-158696
    BChE/MAO-B-IN-1
    BChE/MAO-B-IN-1 (compound 7) is a dual BChE/MAO-B inhibitor with IC50 values ​​of 375 nM and 20 nM, respectively. BChE/MAO-B-IN-1 protects against oxidative damage induced by H2O2 and 6-OHDA in SH-SY5Y cells. BChE/MAO-B-IN-1 can penetrate the central nervous system in a cell model that mimics the blood-brain barrier. BChE/MAO-B-IN-1 can be used in the study of neurological diseases such as Alzheimer's disease (AD).
    BChE/MAO-B-IN-1
  • HY-158765
    Leuco ethyl violet 4865-00-3
    Leuco ethyl violet is a photooxidation catalyst for amyloid selectivity and blood-brain barrier (BBB) permeability. Leuco ethyl violet can be used in the study of Alzheimer's disease (AD).
    Leuco ethyl violet
  • HY-158794
    Lentztrehalose B 1808096-67-4
    Lentztrehalose B is a dehydroxylated analog of trehalose A, possessing antioxidant properties that can be used in research on neurodegenerative diseases and other autophagy-related conditions.
    Lentztrehalose B
  • HY-158805
    4-Methoxy-α-pyrrolidinopropiophenone tosylate 2748561-60-4
    4-Methoxy-α-pyrrolidinopropiophenone (4'-MeO-α-ppp) tosylate is a biomolecule.
    4-Methoxy-α-pyrrolidinopropiophenone tosylate
  • HY-158806
    3,4-DHMA TFA 2704135-58-8
    3,4-DHMA (3,4-Dihydroxymethamphetamine) TFA is an active metabolite of 3,4-MDMA.
    3,4-DHMA TFA
  • HY-158873
    N,N-Dihexyl sphingosine (d18:1/6:0/6:0) 2377379-53-6
    N,N-Dihexyl sphingosine (d18:1/6:0/6:0) (N,N-Dihexyl-D-erythro-sphingosine) is a synthetic analog of C18-Ceramide (HY-100355).
    N,N-Dihexyl sphingosine (d18:1/6:0/6:0)
  • HY-158927
    5-Chloro-2-thiothinone hydrochloride 2903386-66-1
    5-Chloro-2-thiothinone (5-Chloro bk-MPA) hydrochloride is structurally similar to known stimulants.
    5-Chloro-2-thiothinone hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity